Ambit Biosciences Corporation is a biopharmaceutical company. The Company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. The Company's lead drug candidate, quizartinib, is in Phase IIb clinical development in patients with relapsed/refractory acute myeloid leukemia (AML). The Company's second drug candidate in clinical development, AC410, is a potent, selective, orally-administered, small molecule inhibitor of Janus kinase 2 (JAK2) that has potential utility for the treatment of autoimmune and inflammatory diseases. The Company's third program consists of two selective small molecule compounds, AC708 and AC855, which inhibit the colony-stimulating factor-1 receptor (CSF1R), a receptor tyrosine kinase.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Symbol: NASDAQ:AMBI
- CUSIP: N/A
- Web: N/A
- 50 Day Moving Avg: $40.00
- 200 Day Moving Avg: $36.00
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -7.50
- P/E Growth: 0
Frequently Asked Questions for Ambit Biosciences Corp (NASDAQ:AMBI)
What is Ambit Biosciences Corp's stock symbol?
Ambit Biosciences Corp trades on the NASDAQ under the ticker symbol "AMBI."
How were Ambit Biosciences Corp's earnings last quarter?
Ambit Biosciences Corp (NASDAQ:AMBI) posted its quarterly earnings results on Tuesday, May, 6th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.47) by $0.03. The business earned $0.03 million during the quarter, compared to analysts' expectations of $3.50 million. View Ambit Biosciences Corp's Earnings History.
Who are some of Ambit Biosciences Corp's key competitors?
Some companies that are related to Ambit Biosciences Corp include Orange Belgium (MBSRF), Apple (AAPL), Alphabet (GOOGL), Alphabet (GOOG), Microsoft Corporation (MSFT), Amazon.com (AMZN), Facebook (FB), Premier Foods Spon (PRRFY), Berkshire Hathaway (BRK-A), Nestle SA (NSRGY), Industrial & Cmrcl Bnk f China Ltd (IDCBY), RDS-A (RDS-A), Roche Holding (RHHBY), Comcast Corporation (CMCSA), Intel Corporation (INTC), Cisco Systems (CSCO), Amgen (AMGN) and LVMH Moet Hennessy Louis Vuitton SE (LVMUY).
How do I buy Ambit Biosciences Corp stock?
Shares of Ambit Biosciences Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ambit Biosciences Corp's stock price today?
MarketBeat Community Rating for Ambit Biosciences Corp (NASDAQ AMBI)MarketBeat's community ratings are surveys of what our community members think about Ambit Biosciences Corp and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Ambit Biosciences Corp stock can currently be purchased for approximately $15.60.
Consensus Ratings for Ambit Biosciences Corp (NASDAQ:AMBI) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Ambit Biosciences Corp (NASDAQ:AMBI)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Ambit Biosciences Corp (NASDAQ:AMBI)Earnings History by Quarter for Ambit Biosciences Corp (NASDAQ AMBI)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/12/2014||Q2 2014||($0.58)||($0.68)||$0.03 million||$0.03 million||View||Listen|
|5/6/2014||Q1||($0.47)||($0.50)||$3.50 million||$0.03 million||View||Listen|
Earnings Estimates for Ambit Biosciences Corp (NASDAQ:AMBI)
Current Year EPS Consensus Estimate: $-1.99 EPS
Next Year EPS Consensus Estimate: $-2.08 EPS
Dividend History for Ambit Biosciences Corp (NASDAQ:AMBI)
No dividend announcements for this company have been tracked by MarketBeat.com
Headline Trends for Ambit Biosciences Corp (NASDAQ:AMBI)
Latest Headlines for Ambit Biosciences Corp (NASDAQ:AMBI)
Ambit Biosciences Corp (AMBI) Chart for Thursday, July, 20, 2017